Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 329-339

  Ryan, R M ^a,b   Green, J ^b   Williams, P J ^a   Tazzyman, S ^a   Hunt, S ^b   Harmey, J H ^c   Kehoe, S C ^d   Lewis, C E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA VECTOR; CYTOLYSIN; GENE THERAPY AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TUMOR CELL DESTRUCTION; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR SPHEROID;

ANIMALS; CELL DEATH; CELL HYPOXIA; COCULTURE TECHNIQUES; ESCHERICHIA COLI PROTEINS; FEMALE; GENE TARGETING; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HEMOLYSIN PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; NECROSIS; SALMONELLA TYPHIMURIUM; SPHEROIDS, CELLULAR; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

BACTERIA (MICROORGANISMS); MURINAE; SALMONELLA TYPHIMURIUM;

EID: 62549130694     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.188     Document Type: Article

References (49)

1. Brown JM. The hypoxic cell: A target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59: 5863-5870.
2. Vaupel PW, Hockel M. Oxygenation Status of Humans Tumours: A Reappraisal Using Computerized pO2 Histography. Gustav Fischer Verlag: Germany, 1995.
3. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006; 28: 84-94.
4. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000; 181: 1996-2002.
5. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
6. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997; 57: 4537-4544.
7. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-225.
8. Green J, Bennett B, Jordan P, Ralph ET, Thomson AJ, Guest JR. Reconstitution of the [4Fe-4S] cluster in FNR and demonstration of the aerobic-anaerobic transcription switch in vitro. Biochem J 1996; 316 (Pt 3): 887-892.
9. Khoroshilova N, Beinert H, Kiley PJ. Association of a polynuclear iron-sulfur center with a mutant FNR protein enhances DNA binding. Proc Natl Acad Sci USA 1995; 92: 2499-2503.
10. Jordan PA, Thomson AJ, Ralph ET, Guest JR, Green J. FNR is a direct oxygen sensor having a biphasic response curve. FEBS Lett 1997; 416: 349-352.
11. Kiley PJ, Beinert H. The role of Fe-S proteins in sensing and regulation in bacteria. Curr Opin Microbiol 2003; 6: 181-185.
12. del Castillo FJ, Leal SC, Moreno F, del Castillo I. The Escherichia coli K-12 sheA gene encodes a 34-kDa secreted haemolysin. Mol Microbiol 1997; 25: 107-115.
13. Ludwig A, Tengel C, Bauer S, Bubert A, Benz R, Mollenkopf HJ et al SlyA, a regulatory protein from Salmonella typhimurium, induces a haemolytic and pore-forming protein in Escherichia coli. Mol Gen Genet 1995; 249: 474-486.
14. Oscarsson J, Mizunoe Y, Uhlin BE, Haydon DJ. Induction of haemolytic activity in Escherichia coli by the slyA gene product. Mol Microbiol 1996; 20: 191-199.
15. Bjornheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 870-876.
16. Kivisaari J, Niinikoski J. Effects of hyperbaric oxygenation and prolonged hypoxia on the healing of open wounds. Acta Chir Scand 1975; 141: 14-19.
17. Stevens CR, Williams RB, Farrell AJ, Blake DR. Hypoxia and inflammatory synovitis: Observations and speculation. Ann Rheum Dis 1991; 50 124-132.
18. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449-6465.
19. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981; 291: 238-239.
20. Khan SA, Everest P, Servos S, Foxwell N, Zahringer U, Brade H et al A lethal role for lipid A in Salmonella infections. Mol Microbiol 1998; 29: 571-579.
21. del Castillo FJ, Moreno F, del Castillo I. Characterization of the genes encoding the sheA haemolysin in Escherichia coli O157:H7 and Shigella flexneri 2a. Res Microbiol 2000; 151: 229-230.
22. Oscarsson J, Westermark M, Lofdahl S, Olsen B, Palmgren H, Mizunoe Y et al. Characterization of a pore-forming cytotoxin expressed by Salmonella enterica serovars typhi and paratyphi A. Infect Immun 2002; 70: 5759-5769.
23. Ludwig A, Bauer S, Benz R, Bergmann B, Goebel W. Analysis of the slyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12. Mol Microbiol 1999; 31: 557-567.
24. Oscarsson J, Mizunoe Y, Li L, Lai XH, Wieslander A, Uhlin BE. Molecular analysis of the cytolytic protein ClyA (sheA) from Escherichia coli. Mol Microbiol 1999; 32: 1226-1238.
25. Pecota DC, Kim CS, Wu K, Gerdes K, Wood TK. Combining the hok/sok, parDE, and pnd postsegregational killer loci to enhance plasmid stability. Appl Environ Microbiol 1997; 63: 1917-1924.
26. Janat-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004; 9: 829-836.
27. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003; 2003: 194-201.
28. Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, Court DL. An efficient recombination system for chromosome engineering in Escherichia coli. Proc Natl Acad Sci USA 2000; 97: 5978-5983.
29. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-152.
30. Bugelski PJ, Kirsh R, Buscarino C, Corwin SP, Poste G. Recruitment of exogenous macrophages into metastases at different stages of tumor growth. Cancer Immunol Immunother 1987; 24: 93-98.
31. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98: 15155-15160.
32. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: A review. Oncol Res 1997; 9: 313-325.
33. Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Therapy 2002; 9: 1403-1411.
34. Mengesha A, Dubois L, Lambin P, Landuyt W, Chiu RK, Wouters BG et al Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol Ther 2006; 5: 1120-1128.
35. Atkins A, Wyborn NR, Wallace AJ, Stillman TJ, Black LK, Fielding AB et al. Structure-function relationships of a novel bacterial toxin, hemolysin E. The role of alpha G. J Biol Chem 2000; 275: 41150-41155.
36. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209-211.
37. Lodge J, Williams R, Bell A, Chan B, Busby S. Comparison of promoter activities in Escherichia coli and Pseudomonas aeruginosa: use of a new broad-host-range promoter-probe plasmid. FEMS Microbiol Lett 1990; 55: 221-225.
38. Bell A, Busby S. Location and orientation of an activating region in the Escherichia coli transcription factor, FNR. Mol Microbiol 1994; 11: 383-390.
39. Hutchison III CA, Phillips S, Edgell MH, Gillam S, Jahnke P, Smith M. Mutagenesis at a specific position in a DNA sequence. J Biol Chem 1978; 253: 6551-6560.
40. Wyborn NR, Clark A, Roberts RE, Jamieson SJ, Tzokov S, Bullough PA et al. Properties of haemolysin E (HlyE) from a pathogenic Escherichia coli avian isolate and studies of HlyE export. Microbiology 2004; 150: 1495-1505.
41. Norte VA, Stapleton MR, Green J. PhoP-responsive expression of the Salmonella enterica serovar Typhimurium slyA gene. J Bacteriol 2003; 185: 3508-3514.
42. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999; 81: 1311-1317.
43. Miller J. Assay of B-galactosidase. Cold Spring Horbor Laboratory Press: New York, 1972.
44. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163: 1233-1243.
45. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004; 64: 6101-6108.
46. Griffiths L, Binley K, Iqball S, Kan O, Maxwell P, Ratcliffe P et al The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Therapy 2000; 7: 255-262.
47. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
48. Shabsigh A, Ghafar MA, de la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001; 81: 437-444.
49. Raleigh JA, Chou SC, Tables L, Suchindran S, Varia MA, Horsman MR. Relationship of hypoxia to metallothionein expression in murine tumors. Int J Radiat Oncol Biol Phys 1998; 42: 727-730.